Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Drug Discovery
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 291177
Licensor Compound means any 5-HT6 receptor antagonist for which Licensor as of the Effective Date has rights, whether by reason of its own conception of such antagonist, or under agreement with a Third Party, and are Covered by Licensor Patent Rights. Licensor Compounds shall include any 5-HT6 receptor antagonist for which Licensee during the term of this Agreement has rights by reason of its own conception of such antagonist and which also is Covered by the Licensor Patent Rights. A list of the Licensor Compounds shall be updated from time-to-time.
Licensee Product means any pharmaceutical product that includes, in whole or as a component, any Licensee Compound as an active ingredient thereof.
Licensee Compound means any 5-HT6 receptor antagonist for which Licensee as of the Effective Date or during the term of this Agreement has rights, by reason of its own conception of such antagonist, and are Covered by Licensee Patent Rights, but are not covered by the Licensor Patent Rights. A list of the Licensee Compounds shall be updated from time-to-time.
Licensor Patent Rights means all Patent Rights that Licensor owns, or otherwise has the right to grant the licenses herein relating to 5-HT6 receptor antagonists as updated from time-to-time, including (a) any patents issuing from any such patent applications listed hereto and (b) any divisional applications, continuation applications, continuation-in-part applications, substitutions, extensions, supplementary protection certificates, reissues, reexaminations, renewals or the like related to the patents and patent applications listed hereto. Licensor Patent Rights do not include Licensors non-exclusive license from NIH to the 5-HT6 receptor patents.
6,100,291 – Pyrrolidine-indole compounds having 5-HT.sub.6 affinity
6,133,287 – Piperidine-indole compounds having 5-HT.sub.6 affinity
6,251,893 – Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
Licensee Patent Rights means all Patent Rights that Licensee owns relating to 5-HT6 receptor antagonists as updated from time-to-time, including (a) any patents issuing from any such patent applications listed hereto and (b) any divisional applications, continuation applications, continuation-in-part applications, substitutions, extensions, supplementary protection certificates, reissues, reexaminations, renewals or the like related to the patents and patent applications listed.
U.S. Patent Application No. 11/676,203 – Compounds having 5-HT6 receptor affinity
U.S. Provisional Patent Application No. 60/890,324 – 6 substituted compounds having 5-HT6 receptor affinity
IPSCIO Record ID: 310407
Patent
U.S. Patent No. 5,506,207, issued April 9, 1996, entitled, 'GnRH Antagonists XIII'
GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads and may be used to treat steroid-dependent tumors.
The term Patent Rights shall mean the inventions claimed in the patents and patent applications described below
(a) Patent applications listed in agreement and patents issuing therefrom.
(b) Patents listed U.S. Patent No. 5,506,207, issued April 9, 1996, entitled, 'GnRH Antagonists XIII'.
(c) Divisional applications, provisional applications, and continuation applications that claim the benefit of priority to any of the patents described in (a) or (b) or patent applications described in (a) or (b) and patents issuing therefrom.
(d) Continuation-in-part applications only to the extent the claimed inventions are supported by the patents described in (a) or (b) or patent applications described in (a) or (b) and patents issuing therefrom.
(e) Reissue patents, extensions (including extensions under the United States Patent Term Restoration Act), renewals, substitutions and additions thereof, and reexamination patents related to patents described in (a), (b), (c) and (d).
(f) Any and all foreign counterparts of the patent applications and patents described in (a), (b), (c), (d) and (e).
Licensor is the owner of certain Patent Rights (as hereinafter defined), an Institution that explores to understand neuroscience, genetics, immunology, plant biology and more.
MER 104 is under development for the treatment of hormone-sensitive prostate cancer. MER 104 is a gonadotropin-releasing hormone, or GnRH, antagonist formulated using GIPET technology designed to provide an oral dosage alternative to current therapies, all of which are injectable. An oral product would eliminate the inconvenience of injection therapy. It may also avoid severe allergic reactions that have been encountered with some injectable GnRH antagonists and allow tailored dosing regimens.
Licensee is a specialty pharmaceutical company engaged in the development of improved oral dosage forms of drugs that are poorly absorbed.
IPSCIO Record ID: 372521
Licensee has the right to develop and commercialize the PET Ligand as set forth.
Licensor patents and technology relate to Imidazole Derivatives. The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).
The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.
The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.
The term EVT 101 shall mean xO-4394127.
The term EVT 103 shall mean xO-0717626.
The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.
IPSCIO Record ID: 281186
Lead Compound shall mean a Substance designated by the RMC as suitable for initial development against a Current Program Target within the Field based upon results of screening performed pursuant to this agreement. Lead Compounds may be selected as Collaboration Lead Compounds.
Research Compound shall mean any compound that is based upon a Substance that agonizes or antagonizes a Current Program Target and that is made, created, discovered, identified, invented, synthesized, optimized or acquired by or on behalf of either Party pursuant to the Research Plan, or otherwise in the course of the Program. Research Compounds may be selected as Collaboration Lead Compounds.
Program Patents shall mean patents and patent applications, both foreign and domestic, including without limitation all substitutions, provisionals, continuations, continuations-in-part, divisionals, extensions, reexaminations, reissues, renewals, supplementary protection certificates and inventors certificates, that are owned or controlled by either Party or both Parties and claim Program Inventions made during the Term in the course of the discovery, research, Pre-Clinical Development, Development and commercialization of Substances, Lead Compounds, Research Compounds, Collaboration Lead Compounds, Independent Lead Compounds, Products or Independent Products pursuant to the Program. Program Patents shall exclude Research Compound Patents and Program Know-How.
Licensor Technology shall mean, collectively, the Patent Rights and the Know-How owned or controlled by Licensor.
RMC shall mean the research management committee.
MC shall mean the marketing committee.
The deal is for the discovery, development and commercialization of products to treat metabolic diseases. Metabolic syndrome is a cluster of conditions that occur together, increasing your risk of heart disease, stroke and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.
This collaboration agreement is to research and develop orphan nuclear receptor agonists and antagonists.
IPSCIO Record ID: 279355
License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.
Collaboration Compound shall mean a Licensor Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensee Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC. A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensor or Licensee or their Affiliates to protect any compound in category (i), (ii) or (iii) above. A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above. For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensee Compound, Licensor Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound. Joint Research Committee or “JRC†shall mean the entity organized to manage the scientific implementation of the Collaboration.
Licensee IP shall mean Licensee Patents and Licensee Know-how.
Collaboration IP shall mean Collaboration Patents and Collaboration Know-how. Collaboration IP shall not include Licensor IP or Licensee IP.
Licensor IP shall mean Licensor Patents and Licensor Know-how. Licensor IP shall not include any intellectual property owned or licensed by Licensor or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).
Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the effective date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the Effective Date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.
Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensee, Licensor or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensor or Licensee during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensee Patents or Licensor Patents.
Licensor Compound shall mean any compound brought to the Collaboration by Licensor, which is Controlled by Licensor at or after the Effective Date, and which is proprietary to Licensor by virtue of being within the Licensor IP.
Licensor Field shall mean, with respect to each Collaboration Compound for which Licensor has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
Licensee Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.
